Table 2. Anti-HAV# in recipients of LA-1 and H2 vaccines during 3 y follow-up+.
| Month* | LA-1 Vaccine Group | H2 Vaccine Group | ||||||
| n | (+) | % | Anti-HAV GMT (95%CI^ ) | n | (+) | % | Anti-HAV GMT (95%CI^ ) | |
| 3 | 119 | 88 | 74.0 | 122.7 (84.6–178.0) | 102 | 94 | 92.2 | 126.2 (99.9–159.1) |
| 6 | 121 | 104 | 86.0 | 99.4 (78.5–125.7) | 101 | 88 | 87.1 | 90.7 (71.9–114.5) |
| 12 | 51 | 41 | 80.4 | 91.7 (68.5–122.4) | 101 | 81 | 80.2 | 81.0 (63.9–102.8) |
| 24 | 92 | 73 | 79.4 | 90.5 (71.4–114.8) | 74 | 56 | 75.7 | 82.1 (61.7–109.3) |
| 36 | 63 | 50 | 79.4 | 91.0 (72.5–114.3) | 64 | 48 | 75.0 | 80.8 (60.1–108.6) |
+ This table was adopted with permission from Xu ZY, et al. Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H2 Strains and LA-1 strains). Zhong Hua Yi Xue Za Zhi 2002; 82:678–81. *Month after vaccination. ^95% Confidence Interval. #anti-HAV IgG.